Maintenance bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: Do we finally know the best schedule?

European Urology

Volumn 63, Issue 3, 2013, Pages 473-474

  Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; OFLOXACIN;

BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CLINICAL TRIAL; CYSTECTOMY; CYSTITIS; DISEASE FREE SURVIVAL; DRUG COST; EDITORIAL; HUMAN; PRIORITY JOURNAL;

BCG VACCINE; CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; URINARY BLADDER NEOPLASMS;

EID: 84872908696     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.023     Document Type: Editorial

References (6)

1. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
2. P.-U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
3. J. Oddens, M. Brausi, and R. Sylvester Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
4. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
5. A.P. van der Meijden, M. Brausi, V. Zambon, W. Kirkels, C. de Balincourt, R. Sylvester members of the EORTC Genito-Urinary Group Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial J Urol 166 2001 476 481 (Pubitemid 32652226)
6. S. van den Bosch, and J.A. Witjes Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review Eur Urol 60 2011 493 500